Docetaxel- and 5-FU-concurrent radiotherapy in patients presenting unresectable locally advanced pancreatic cancer: a FNCLCC-ACCORD/0201 randomized phase II trial's pre-planned analysis and case report of a 5.5-year disease-free survival

BACKGROUND: To explore possible improvement in the treatment of locally advanced pancreatic carcinoma (LAPC) we performed a randomized, non-comparative phase II study evaluating docetaxel - plus either daily continuous 5 FU or weekly cisplatin concurrent to radiotherapy. We report here the results o...

Descripción completa

Detalles Bibliográficos
Autores principales: Oberic, Lucie, Viret, Frédéric, Baey, Charlotte, Ychou, Marc, Bennouna, Jaafar, Adenis, Antoine, Peiffert, Didier, Mornex, Françoise, Pignon, Jean-Pierre, Celier, Patrice, Berille, Jocelyne, Ducreux, Michel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3191360/
https://www.ncbi.nlm.nih.gov/pubmed/21943032
http://dx.doi.org/10.1186/1748-717X-6-124

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3191360/
https://www.ncbi.nlm.nih.gov/pubmed/21943032
http://dx.doi.org/10.1186/1748-717X-6-124

Ejemplares similares